EUVIMEDEUVIMED entdecken
Crossref

Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study

Lieming Ding, Xiaobin Yuan, Yang Wang, Min Yang, Pengxiang Wu, Hui Chen, Yu Yun, Zhilin Shen, Dong Ji, Yongbin Ma

Asia-Pacific Journal of Clinical Oncology · 2024

DOI: 10.1111/ajco.14091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Lieming Ding und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Betta Pharmaceuticals Co., Ltd, Hangzhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Anaplastic Lymphoma Kinase, Carcinoma, Adenosquamous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Betta Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To report the efficacy and safety of ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, in treating patients with ALK‐positive advanced lung squamous cell carcinoma (LUSC) or lung adenosquamous carcinoma (LASC) in China.

Methods

This retrospective study analyzed data for 36 advanced‐stage patients with ALK‐positive LUSC (cohort A) and 13 patients with ALK‐positive LASC (cohort B) between December 16, 2020 and December 16, 2021. All patients received once‐daily ensartinib 225 mg. Outcome analysis included the demographic characteristics, tumor response, progression‐free survival (PFS), and treatment‐related adverse events (TRAE).

Results

Among the 49 patients, the majority were under 65 years old (73.5%), non‐smokers (85.7%), had an Eastern Cooperative Oncology Group Performance Status of 0–1 (77.6%), and were at stage IV (71.4%). All patients were included in the efficacy and safety analysis. Seven PFS events were reported in cohort A while no patients experienced PFS events in cohort B. The median PFS was not estimable for both cohorts. In cohort A, the objective response rate (ORR) was 63.9%, and the disease control rate (DCR) was 83.3%. In the cohort B, the ORR was 76.9% and the DCR was 100.0%. Rash was the only TRAE reported in the cohort A (8.3%) and cohort B (23.1%). No patients had grade 3 or higher TRAE.

Conclusion

Ensartinib has been tentatively proven favorable efficacy and tolerability in the treatment of patients with ALK‐positive advanced LUSC or LASC in the real‐world. However, confirmatory studies are still needed in larger sample sizes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAnaplastic Lymphoma KinaseCarcinoma, AdenosquamousHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultCarcinoma, Squamous CellProtein Kinase InhibitorsPiperazinesPyridazines

Stichwörter der Autor:innen

adenosquamous carcinomaanaplastic lymphoma kinaseensartinibnon‐small cell lung cancersquamous cell carcinoma

Substanzen

ensartinibAnaplastic Lymphoma KinaseProtein Kinase InhibitorsALK protein, humanPiperazinesPyridazines

Autor:innen und Institutionen

  • Department of Medicine, Betta Pharmaceuticals Co., Ltd, Hangzhou, China.

Förderung

  • Betta Pharmaceuticals

Zitieren

APA

Ding, L., Yuan, X., Wang, Y., Yang, M., Wu, P., Chen, H., Yun, Y., Shen, Z., Ji, D., & Ma, Y. (2024). Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14091

Vancouver

Ding L, Yuan X, Wang Y, Yang M, Wu P, Chen H, et al. Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.14091

BibTeX
@article{Ding2024,
  author = {Ding, Lieming and Yuan, Xiaobin and Wang, Yang and Yang, Min and Wu, Pengxiang and Chen, Hui and Yun, Yu and Shen, Zhilin and Ji, Dong and Ma, Yongbin},
  title = {Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1111/ajco.14091}
}
Kostenlos starten →